Phio Pharmaceuticals Corp. PHIO 深 滬
等待開盤 10-10 09:30:00 美东时间
2.355
-0.065
-2.69%
華盛通- 最 高2.45
- 今 開2.45
- 成交量 5.33万股
- 最 低 2.33
- 昨 收 2.42
- 總市值 1348.66万
- 52周最高 9.79
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 0.9657
- 委 比 -76.99%
- 總股本 572.68万
- 歷史最高 3118.50
- 量 比 0.65
- 振 幅 4.96%
- 歷史最低 0.9657
- 每 手 1
- 風險率 2.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phio Pharma To Present PH-762 INTASYL siRNA Skin Cancer Trial Progress And Strategic Outlook At Life Sciences Future Conference Sept. 25-26, 2025
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp.
09-18 19:48
Phio Pharmaceuticals Stockholders Approve Key 2025 Proposals
The latest announcement is out from Phio Pharmaceuticals ( ($PHIO) ). At the An...
09-16 04:39
Phio Pharmaceuticals to Attend Global Investment Conference
The latest announcement is out from Phio Pharmaceuticals ( ($PHIO) ). On Septem...
09-03 20:28
Phio Pharmaceuticals Has Been Issued Canadian Patent Number 3027780 Titled "REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS"
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3027780/summary.html
09-03 03:58
HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
08-15 19:17
Phio Pharma Q2 EPS $(0.45) Misses $(0.36) Estimate
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.36) by 25 percent. This is a 87.57 percent increase over losses of $(3.62) per share from the
08-15 04:19
Phio Pharmaceuticals Issues New Warrants for $2.5M
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an update. On July 25, 2025, Phi...
07-31 04:51
Phio Pharmaceuticals Announces New Manufacturing Agreement
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an announcement. On July 25, 202...
07-26 01:57
Phio Pharmaceuticals shares are trading higher after the company announced a comprehensive U.S. drug substance development services agreement for its lead compound PH-762.
Phio Pharmaceuticals shares are trading higher after the company announced a co...
07-25 20:46
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
